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Background: The Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS) trial
demonstrated that early aggressive statin therapy in patients with ACS significantly reduces plaque volume (PV).
Advanced glycation end products (AGEs) and the receptors of AGEs (RAGE) may lead to angiopathy in diabetes
mellitus (DM) and may affect on the development of coronary PV. The present sub-study of JAPAN-ACS investigates
the association between AGEs and RAGE, and PV.
Methods: Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) was undertaken,
followed by the initiation of statin treatment (either 4 mg/day of pitavastatin or 20 mg/day of atorvastatin), in
patients with ACS. In the 208 JAPAN-ACS subjects, PV using IVUS in non-culprit segment > 5 mm proximal or distal to
the culprit lesion and, serum levels of AGEs and soluble RAGE (sRAGE) were measured at baseline and 8–12 months
after PCI.
Results: At baseline, no differences in the levels of either AGEs or sRAGE were found between patients with DM and
those without DM. The levels of AGEs decreased significantly with statin therapy from 8.6 ± 2.2 to 8.0 ± 2.1 U/ml
(p < 0.001), whereas the levels of sRAGE did not change. There were no significant correlations between changes in PV
and the changes in levels of AGEs as well as sRAGE. However, high baseline AGEs levels were significantly associated
with plaque progression (odds ratio, 1.21; 95% confidence interval, 1.01 - 1.48; p = 0.044) even after adjusting for DM in
multivariate logistic regression models.
Conclusions: High baseline AGEs levels were associated with plaque progression in the JAPAN-ACS trial. This
relationship was independent of DM. These findings suggest AGEs may be related to long-term glucose control and
other oxidative stresses in ACS.
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Recent advances in plaque imaging have enabled the
quantitative measurement of plaque volume (PV) and
their characteristics[1,2]. Several clinical trials have
observed significant plaque regression after treatment
with HMG CoA-reductase inhibitors (statins) using
intravascular ultrasound (IVUS) [3-6].
Using IVUS, the Japan Assessment of Pitavastatin and
Atorvastatin in Acute Coronary Syndrome (JAPAN–ACS)
trial has demonstrated that early aggressive statin therapy
(either pitavastatin or atorvastatin) in patients with acute
coronary syndrome (ACS) significantly reduces PV of
non-culprit coronary lesions during the first 8–12 months
after ACS [7]. In this trial, the regression of PV induced
by statin therapy was smaller in diabetic patients com-
pared with non-diabetic patients although the degree of
low density lipoprotein cholesterol (LDL–C) reduction
was similar between the diabetic and non-diabetic patients
[8]. Recent observations from a coronary atherosclerosis
study measuring the effects of rosuvastatin using intravas-
cular ultrasound in Japanese subjects (COSMOS) indi-
cated that poor baseline glycemic control were associated
with the plaque progression [9]. Similar observations were
consistently reported from recent IVUS trials that indi-
cated that diabetic plaque has specific characteristics and/
or that diabetic patients may have specific pathophysi-
ology that attenuates the effect of statins on atheroscle-
rotic plaque [10-13].
Several causal pathways have been proposed regarding
atherogenesis in diabetes mellitus including enhanced pro-
duction of reactive oxygen species, activation of protein
kinase C, stimulation of the polyol pathway, and postpran-
dial hyperglycemia[14]. Advanced glycation end products
(AGEs) and receptors of AGEs (RAGE) may also contrib-
ute to the development of micro- and macroangiopathy
in diabetes mellitus which may affect coronary plaque
progression as well as vascular remodeling [15-19]. The
present sub-study of JAPAN-ACS investigates the role of
serum levels of AGEs and soluble RAGE (sRAGE) on




The design of the JAPAN-ACS study has been previously
published [7-9]. In brief, the JAPAN–ACS study, which
was conducted with the participation of 33 centers
(Additional file 1), was a prospective, randomized, open-
label, parallel-group study with blind endpoint evalu-
ation. It examined the possible effect of 8–12 months of
treatment with a statin on coronary plaque regression,
measured using IVUS, at nonculprit lesions of the
culprit vessel in patients with ACS. ACS patients satisfy-
ing all inclusion criteria were selected for participationin the study after they underwent successful, intravascular
ultrasound-guided percutaneous coronary intervention
(PCI). The patients were randomized within 72 hours of
PCI to receive either 4 mg of pitavastatin or 20 mg of ator-
vastatin daily. IVUS examination was performed at base-
line and was repeated 8–12 months after the start of statin
treatment. Because there was no significant difference in
percent change in PV between the two statin groups, the
following analyses were evaluated in the full analysis set of
patients. This JAPAN–ACS subgroup analysis investigated
the relationships between the serum levels of AGEs or
sRAGE and change of PV. The JAPAN–ACS study and
related sub-studies were conducted according to the
Declaration of Helsinki and with the approval of the insti-
tutional review boards of all the 33 participating institu-
tions. Written informed consent to participate was
obtained from all patients enrolled in the study.
Biochemical analysis
Blood examinations for levels of lipid and fasting blood glu-
cose levels, hemoglobin A1c (HbA1c), and serum levels of
AGEs and sRAGE were performed at baseline and at
follow-up after 8–12 months. Serum levels of the lipid pro-
file and blood examinations as well as the levels of AGEs
and sRAGE were measured at the centralized laboratory
(Hokuriku University, Kanazawa and Kurume University,
Kurume). Measurement of the serum levels of AGEs was
performed using a competitive ELISA [20]. In this study, 1
unit (U) corresponds to 1 μg of glyceraldehyde-derived
AGE-bovine serum albumin standard. sRAGE was
determined using a commercially available ELISA kit
(QuantikineW, R&D systems, Minneapolis, MN, USA)
according to the supplier’s recommendation. The
HbA1c (%) was estimated as a National Glycohemoglobin
Standardization Program (NGSP) equivalent value (%) cal-
culated using the formula HbA1c (%) = 1.02 × HbA1c
(JDS; %) + 0.25% [21]. Low density lipoprotein- cholesterol
(LDL-C) was calculated using the Friedewald formula [22].
Intravascular ultrasound examination
After IVUS-guided PCI of the culprit lesion in patients
with ACS, IVUS examination was performed in the long-
est and least angulated segment of the culprit vessel, if it
met the previously described inclusion criteria. Following
intracoronary administration of 200 μg of nitroglycerin, a
40-MHz, 2.6F IVUS catheter (Atlantis SR Pro2, Boston
Scientific, Natik, MA, USA) was advanced into the culprit
vessel, and the transducer was positioned as far distally as
could be safely reached. This procedure was designed to
select the longest-possible vessel segment for analysis. A
motorized pullback device withdrew the transducer at a
speed of 0.5 mm/s. The consoles used were ClearView or
Galaxy 2 systems (Boston Scientific, Natik, MA, USA).
The same imaging system with the same type of IVUS
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evaluations.
Two independent experienced investigators, who were
unaware of the patient group allocation, performed the
quantitative IVUS analysis at the central core -laboratory
(Yamaguchi University, Ube) as described previously [7].
In brief, the target segment was determined as a non-
culprit coronary artery segment >5 mm proximal or distal
to the culprit lesion with a reproducible index, usually
abranch site, on the PCI vessel. Spotty calcification, side
vein, and distances from side branch, orifice, left anterior
descending-left circumflex branch bifurcation, and stent
edge also were referred. Then, every 6 th image (0.1-mm
apart) was manually traced on a commercially available
software for IVUS measurement (echoPlaque2, INDEC sys-
tems Inc., Santa Clara, CA, USA). This software automatic-
ally interpolated the tracings of five cross-sections in
between the two manually traced images. Therefore, the
volume was calculated from segments that were 0.017-mm
thick. The IVUS measurements were performed according
to the standards of the American College of Cardiology and
the European Society of Cardiology [1]. The percent change
in the PV during the observation period was calculated
using following formula: { [ PV (follow-up) - PV (baseline) ]
/ PV (baseline) } × 100. Regression of coronary PV was
defined as percent change in PV <0% and progression of
coronary PV was defined as percent change in PV ≥0%.
Statistical analysis
Continuous variables are presented as the mean ± SD or
median (interquartile range; IQR) according to their dis-
tribution. Categorical variables are expressed as numbers
and percentages. We used Pearson correlations to assess
the relationships between AGEs, sRAGE, fasting blood
glucose, and HbA1c. Within-group and between-group
comparisons were carried out using paired or unpaired
Student’s t-tests for normally distributed data The
Wilcoxon signed rank test or Wilcoxon rank sum test
was used for non-normally distributed data. The chi-
square test or Fisher’s exact test was used for categorical
variables.
To test whether the levels of AGEs or sRAGE were
significantly associated with plaque progression, we
developed logistic regression models with plaque pro-
gression as the independent variable. When either AGEs
or sRAGE were associated with plaque progression in
the univariate model, we developed the multivariate
model. We included in the multivariate model the fol-
lowing variables which were significantly associated with
the degree of coronary PV change in the previous report
of the JAPAN–ACS sub-study [8], diabetes mellitus,
baseline PV and baseline remnant like lipoprotein chol-
esterol (RLP-C) in addition to AGEs or sRAGE. The
continuous variables were treated as continuous in thelogistic models, and effects were expressed by odds ratio
(OR) and 95% confidence intervals (CI) for 1 unit incre-
ments against plaque progression.
The relationships between percent changes of PV and
those of serum levels AGEs as well as sRAGE.. A value
of p < 0.05 was considered significant. All statistical ana-
lyses were performed using the SPSS, Ver.11.0 (SPSS
Inc, Chicago, Illinois).
Results
Baseline AGEs and sRAGE levels and their changes
A total of 208 ACS patients, for whom frozen serum sam-
ples were available to measure levels of AGEs and sRAGE,
were enrolled in this study. The baseline serum levels of
AGEs and sRAGE in these patients were 8.6 ± 2.2 U/ml
and 692 (493 – 1037) pg/ml, respectively. The relationship
between baseline characteristics and AGEs or sRAGE level
is shown in Table 1. The serum level of AGEs was higher
in smokers than in non-smokers, and it tended to be
higher in men than in women. No differences in either
AGE or sRAGE levels were observed between diabetic
patients and nondiabetic patients (Table 1).
In addition, there was no correlation between AGEs
or sRAGE levels and either fasting blood glucose levels
(r = 0.08, p = 0.3 for AGEs, r = 0.07, p = 0.3 for
sRAGE), or HbA1c levels (r = 0.09, p = 0.2 for AGEs,
r = 0.09, p = 0.2 for sRAGE).
Levels of AGEs had decreased significantly (8.6 ± 2.2
to 8.0 ± 2.1 U/ml, p < 0.001) upon follow-up (Figure 1),
whereas sRAGE levels had not decreased significantly
[692 (493 – 1037) to 736 (532 – 990) pg/ml, p = 0.4].
The AGEs level in the pitavastatin group (n = 110) had
decreased significantly (8.6 ± 2.0 to 7.7 ± 1.8 U/ml,
p < 0.001), whereas in the atorvastatin group (n = 98) it
had not (8.6 ± 2.4 to 8.3 ± 2.3 U/ml, p = 0.051).
Comparison between patients with plaque regression and
those with plaque progression
Regression of plaque had occurred in 180 patients and
the remaining 28 patients had showed progression.
Comparisons between the two groups in clinical charac-
teristics and laboratory results are shown in Tables 2
and 3, respectively. Patients with plaque regression were
less likely to have diabetes mellitus. In addition, patients
with plaque regression had significantly lower baseline
levels of AGEs than those with progression (8.4 ± 2.2 vs.
9.4 ± 1.9 U/ml, p = 0.032), whereas no significant differ-
ences were observed in the baseline level of sRAGE.
The relationship between serum levels of AGEs and
plaque progression
There was a significant relationship between the baseline
level of AGEs and the progression of PV (OR 1.23, 95% CI
1.02 –1.50, p = 0.030), whereas there was no significant
Table 1 Baseline AGEs and sRAGE levels
Background N = 208 AGEs* (U/mL) P-value sRAGE* (pg/mL) P-value
Statin Atorvastatin 98 8.56 ± 2.35 0.99 736 (494–1099) 0.6
Pitavastatin 110 8.56 ± 2.04 681 (492–1016)
Gender Women 42 8.00 ± 2.22 0.06 704 (413–1104) 0.8
Men 166 8.71 ± 2.17 692 (494–1004)
Diabetes mellitus No 146 8.44 ± 2.14 0.2 692 (481–1015) 0.2
Yes 62 8.86 ± 2.28 755 (552–1096)
Hypertension No 81 8.46 ± 2.22 0.6 684 (489–1022) 0.8
Yes 127 8.63 ± 2.18 718 (494–1095)
Smoking No 112 8.25 ± 2.14 0.028 692 (541–1050) 0.5
Yes 96 8.92 ± 2.20 707 (453–1037)
ST elevation No 74 8.63 ± 2.10 0.7 720 (537–949) 0.8
Yes 134 8.53 ± 2.24 683 (472–1080)
*Data of AGEs were expressed as mean ± SD and those of sRAGE were median (interquartile range). AGEs, Advanced glycation end products; sRAGE, serum
Receptor of AGE.
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progression of PV in univariate models (OR 1.00, 95%
CI 0.999 – 1.000, p = 0.5). Multivariate logistic regression
model with baseline AGEs, diabetes mellitus, baseline PV
and baseline RLP-C showed that baseline level of AGEs
was significantly associated with plaque progression (OR
1.21, 95% CI 1.01 – 1.48, p = 0.044) (Table 4).
Correlation between plaque volume and the change in
serum levels of AGEs or sRAGE
There was no significant correlation between the percent
change in PV and the change in serum levels of AGEsFigure 1 Change in serum AGEs levels (n=208). Data of AGEs were exp
baseline to follow-up (8.6 ± 2.2 to 8.0 ± 2.1 U/ml, p < 0.001). AGEs, Advanc(r = − 0.07, p = 0.3). The percent change in sRAGE levels
during the study period was also not significantly corre-
lated with the percent change in PV (r = − 0.02, p = 0.8).
Discussion
The primary results of JAPAN–ACS indicated that dia-
betes mellitus attenuated the effect of statins in terms of
plaque regression. The present sub-study of JAPAN-
ACS investigates the association between plaque pro-
gression/regression and the serum levels of AGEs as well
as sRAGE. The baseline AGEs level was significantly
higher in patients with plaque progression (8.4 ± 2.2 vs.ressed as mean ± SD. Serum AGE levels decrease significantly from
ed glycation end products.
Table 2 Comparison in clinical characteristics between
patients with plaque regression and progression
Regression Progression P-value
N=180 N=28
Age (yrs) 62.4 ± 10.6 65.8 ± 13.6 0.1
Male 142 (78.9) 24 (85.7) 0.4
BMI (kg/m2) 24.3 ± 3.5 23.6 ± 2.5 0.2
Diabetes mellitus 48 (26.7) 14 (50.0) 0.016
Hypertension 107 (59.4) 20 (71.4) 0.2
Smoking 85 (47.2) 11 (39.3) 0.4
History of prior PCI 12 (6.7) 1 (3.6) 0.5
Type of ACS 0.3
STEMI 113 (62.8) 21 (75.0)
NSTEMI 26 (14.4) 4 (14.3)
UAP 41 (22.8) 3 (10.7)
Culprit Vessel 0.1
RCA 56 (31.1) 14 (50.0)
LAD 99 (55.0) 13 (46.4)
LCX 24 (13.3) 1 (3.6)
LMT 1 (0.6) 0 (0)
Type of stent 0.6
BMS 120 (66.7) 19 (67.9)
DES 57 (31.7) 9 (32.1)
Other than Stent (POBA) 3 (1.7) 0 (0)
Analysis Segment 0.6
Proximal to target site 124 (68.9) 18 (64.3)
Distal to target site 56 (31.1) 10 (35.7)
Use of pitavastatin 96 (53.3) 14 (50.0) 0.7
BMI, body mass index; PCI, percutaneous coronary intervention; ACS, acute
coronary syndrome; STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-
elevation myocardial infarction; UAP, unstable angina pectoris; RCA, right
coronary artery; LAD, left anterior descending artery; LCX, left circumflex
branch; LMT, left main trunk; BMS, bare-metal stent; DES, drug-eluting stent;
POBA, plain old balloon angioplasty.
Data are expressed in numbers (percentage), unless otherwise specified. Age
and BMI are presented as the mean ± SD. * < 0.05 vs. patients with regression.
Table 3 Comparison in laboratory results between
patients with plaque regression and progression
Regression Progression P-value
N=180 N=28
WBC (cells/μl) 9323 ± 3443 9635 ± 1878 0.5
Max CK (IU/L) 1852 ± 1993 1717 ± 1629 0.7
Hb (g/dL) 14.1 ± 1.6 13.7 ± 1.9 0.3
AST (IU/L) 80.2 ± 102.8 79.2 ± 86.9 0.96
ALT (IU/L) 33.9 ± 22.5 35.2 ± 22.4 0.8
γ-GTP (IU/L) 45.7 ± 52.3 57.2 ± 68.3 0.4
Total bilirubin (mg/dL) 0.8 ± 0.3 0.8 ± 0.3 0.2
BUN (mg/dL) 15.3 ± 4.9 15.4 ± 5.2 0.9
Creatinine (mg/dL) 0.81 ± 0.24 0.83 ± 0.19 0.7
Uric acid (mg/dL) 5.4 ± 1.6 5.1 ± 1.7 0.4
TC (mg/dL) 196.1 ± 36.5 196.3 ± 35.4 0.98
LDL-C (mg/dL) 132.1 ± 33.3 131.4 ± 34.0 0.9
TG (mg/dL) 115.2 ± 53.0 115.1 ± 24.0 0.99
HDL-C (mg/dL) 44.0 ± 10.3 45.7 ± 8.8 0.4
RLP-C (mg/dL) 4.2 ± 2.3 4.0 ± 2.3 0.6
hs-CRP(mg/L) 32.8 ± 39.0 48.8 ± 43.9 0.08
FBS (mg/dL) 153.6 ± 61.8 156.9 ± 63.8 0.8
HbA1c (%) 6.3 ± 1.2 6.9 ± 1.7 0.023
AGEs (U/mL) 8.4 ± 2.2 9.4 ± 1.9 0.032
sRAGE (pg/mL) 683 (496–1037) 723 (483–1081) 0.9
WBC, white blood cell counts; CK, creatine kinase; Hb, hemoglobin; AST,
aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-guanosine
5’-triphosphate; BUN, blood urea nitrogen; TC, total cholesterol; LDL-C, low
density lipoprotein-cholesterol; TG, triglyceride; HDL-C, high density
lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; FBS, fasting
blood sugar; HbA1c, haemoglobin A1c; AGEs, Advanced glycation end
products; sRAGE, serum Receptor of AGE.
Data were expressed as the mean ± SD or median (IQR).
Table 4 Variables associated with plaque progression
Parameter OR (95% CI) P-value
Baseline AGEs 1.21 (1.01 - 1.48) 0.044
Diabetes mellitus 2.62 (1.14 - 6.05) 0.024
Baseline plaque volume 1.00 (0.99 - 1.02) 0.6
Baseline RLP-C 0.91 (0.72 - 1.10) 0.4
The continuous variables were treated as continuous in the logistic models,
and effects were expressed by odds ratio for 1 unit increments.
AGEs, Advanced glycation end products; RLP-C, remnant like
particle- cholesterol.
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of diabetes mellitus. In addition, there was no correlation
between the change in AGEs levels and percent change in
PV, although the AGEs levels reduced significantly during
10 months of follow-up. The sRAGE levels did not dem-
onstrate any correlation with plaque progression or re-
gression. Further, in the present study, although the AGEs
levels were not different between patients with diabetes
and those without, they were significantly higher in smo-
kers than in nonsmokers, and they tended to be higher in
men than in women.
There is accumulating evidence that AGEs and RAGE
are implicated in the pathogenesis of various devastating
disorders such as diabetic vascular complications, car-
diovascular disease, Alzheimer’s disease, cancer growth
and metastasis, insulin resistance and non-alcoholicsteatohepatitis [15,16,23-25]. Harmful effects of AGEs
were predominantly observed in large vessels [26-28].
Indeed, it was reported that AGEs decreased large vessel
elasticity and elicited inflammatory and pro-thrombotic
responses in the vessel wall, thereby being involved in vas-
cular complications [26-28]. Furthermore, the expression
levels of AGEs and RAGE were increased in diabetic ath-
erosclerotic lesions [29,30] Because AGEs are generated
not only from Amadori products under hyperglycemic
conditions, but also from dicarbonyl compounds derived
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sugars and other metabolic pathways of glucose [15]. They
include heterogeneous molecules such as carboxymethy-
llysine, pentosidine, and glyceraldehyde-derived AGEs
[23-25]. In the present study, we measured levels of
glyceraldehyde-derived AGEs, which could reflect inflam-
matory oxidative stress conditions and/or hyperglycaemic
states [23-25]. Thus the levels of AGEs measured here may
be influenced by both the presence of diabetes mellitus
and its long-term control of hyperglycemia, and by add-
itional oxidative stress conditions such as smoking status.
In this study, the baseline levels of AGEs were signifi-
cantly higher in patients with plaque progression than in
those without progression, although the reduction in the
levels of AGEs did not correlate with the change in PV.
In the multivariate logistic regression analysis, the pres-
ence of diabetes mellitus and baseline level of AGEs
were significant, independent variables associated with
the plaque progression. This further supports the patho-
logical role for AGEs in accelerated atherosclerosis in
humans.
In the present study, although statin therapy reduced
the levels of AGEs, this reduction did not correlate with
the change in PV. AGEs are hardly degraded and remain
for a long time in diabetic vessels even after glycemic con-
trol and oxidative stress conditions have been improved
[15]. Therefore, the phenomenon of so-called metabolic
memory could be explained, in part, by AGEs [31]. In
other words, the harmful effects of AGEs on plaque pro-
gression may not be easily reversed by short-term statin
therapy. Former smokers remain at an increased risk
for developing lung cancer and cardiovascular disease
even years after they stop smoking [32]. Because this
phenomenon has an interesting analogy to metabolic
memory, and because tobacco smoking is a major en-
vironmental source of AGEs in humans [32], the dele-
terious effects of smoking on atherosclerosis could be
mediated, in part, by AGEs. In this study, the levels
of sRAGE did not show any relationship to plaque
progression or regression. Although RAGE definitely
plays an important role in atherosclerotic progression
[33,34], the value of measuring sRAGE levels remains
uncertain. Further study is warranted.
Although the present study indicated the possible
adverse effect of AGEs on plaque regression during the
statin therapy, some limitations should be considered.
First, AGEs and sRAGE levels were measured in 208 fro-
zen samples from patients who participated in JAPAN–
ACS that only accounted for two-thirds of all participants.
However, the lack of sample did not occur systematically,
and the effects were small if present. Second, the end point
of the JAPAN–ACS trial was the change in total atheroma
volume, whose index may not be affected by the AGE–
RAGE axis. However, given the pivotal role of the AGE–RAGE axis in experimental atherosclerosis [15,28-30], the
present findings could provide some new insight into the
pathophysiology of plaque progression and regression in
patients with ACS. Finally, the number of patients with
plaque progression was small. Thus, to avoid the overload-
ing of multivariate model, we could not include all poten-
tial confounders. We thus used the factors associated with
in the previous study to adjust the confounding as much as
possible.Conclusion
High baseline levels of AGEs were associated with PV
progression in the JAPAN–ACS trial. In addition, this
relationship was independent of the presence of diabetes
mellitus and HbA1c levels. Therefore, the mechanism by
which AGEs affects plaque progression may not be
related to the presence of diabetes mellitus itself, but to
long-term cumulative hyperglycemia and/or oxidative
stress conditions in patients with ACS. Further studies
are needed to elucidate the role of the AGE–RAGE axis
in the progression of atherosclerosis in humans.Additional file
Additional file 1: JAPAN-ACS investigators.
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